Rua Bioscience Strengthens Supply Line with Schroll Medical Agreement
Rua Bioscience is pleased to announce a significant advancement in its commitment to providing high-quality medicinal cannabis products to its key markets. The company has entered into a supply agreement with Schroll Medical of Denmark to cultivate, manufacture and supply medicinal cannabis products, further enhancing its secure supply line options.
The partnership with Schroll Medical marks another positive step for Rua Bioscience. The agreement ensures that Rua's key markets will have access to high-quality medicinal cannabis products, meeting the growing demand globally.
"We are excited to collaborate with Schroll Medical, a renowned player in the medicinal cannabis industry” said Paul Naske, Chief Executive Officer of Rua Bioscience. "This agreement aligns with our strategic plan to establish product pipelines in key international markets that can ultimately be filled with unique medicinal cannabis products using our own varieties expertly selected in Ruatorea, New Zealand."
Schroll Medical are an EU-GMP certified cultivator and manufacturer of medicinal cannabis flower and full spectrum products. They have been cultivating cannabis since 2018 and are well positioned to supply the growing markets within Europe.
"The inclusion of Schroll Medical into our supply chain aligns with our capital light strategy and enables us to adapt to the evolving landscape of the medicinal cannabis industry" added CEO Paul Naske. “We understand the importance of offering a variety of high-quality supply options to meet the unique requirements of patients and prescribers, and this agreement with Schroll Medical will enable us to do that".
For further information please contact:
Paul Naske Chief Executive Officer
+64 21 445 154
But the stock exchange operator's revenue was up.
To join your company account for BusinessDesk and enjoy full access, enter your email and we’ll send you details